NZ569883A - Use of triazole containing compounds for inhibiting 4E activity and proliferation of a cell - Google Patents

Use of triazole containing compounds for inhibiting 4E activity and proliferation of a cell

Info

Publication number
NZ569883A
NZ569883A NZ569883A NZ56988306A NZ569883A NZ 569883 A NZ569883 A NZ 569883A NZ 569883 A NZ569883 A NZ 569883A NZ 56988306 A NZ56988306 A NZ 56988306A NZ 569883 A NZ569883 A NZ 569883A
Authority
NZ
New Zealand
Prior art keywords
eif4e
cells
cell
ribavirin
activity
Prior art date
Application number
NZ569883A
Other languages
English (en)
Inventor
Katherine L B Borden
Biljana Culjkovic
Alex Kentsis
Gordon A Jamieson
Original Assignee
Translational Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translational Therapeutics Inc filed Critical Translational Therapeutics Inc
Publication of NZ569883A publication Critical patent/NZ569883A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ569883A 2005-12-28 2006-12-28 Use of triazole containing compounds for inhibiting 4E activity and proliferation of a cell NZ569883A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75446105P 2005-12-28 2005-12-28
US79404806P 2006-04-22 2006-04-22
US84858306P 2006-09-29 2006-09-29
US85440406P 2006-10-25 2006-10-25
PCT/US2006/049450 WO2007123579A2 (en) 2005-12-28 2006-12-28 Translational dysfunction based therapeutics

Publications (1)

Publication Number Publication Date
NZ569883A true NZ569883A (en) 2011-12-22

Family

ID=38625451

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ569883A NZ569883A (en) 2005-12-28 2006-12-28 Use of triazole containing compounds for inhibiting 4E activity and proliferation of a cell

Country Status (6)

Country Link
EP (1) EP1971690B1 (enExample)
JP (2) JP2009522281A (enExample)
AU (1) AU2006342447B2 (enExample)
CA (1) CA2633715C (enExample)
NZ (1) NZ569883A (enExample)
WO (1) WO2007123579A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5602349B2 (ja) * 2007-11-20 2014-10-08 旭化成ファーマ株式会社 ミゾリビン及び／又はリバビリンの測定方法
WO2009118712A2 (en) * 2008-03-27 2009-10-01 Ecole Polytechnique Federale De Lausanne (Epfl) Novel dihydroxypyrrolidine derivatives as anti-cancer agents
US8599383B2 (en) 2009-05-06 2013-12-03 The Regents Of The University Of California Optical cytometry
WO2013019984A1 (en) * 2011-08-02 2013-02-07 The Regents Of The University Of California Rapid, massively parallel single-cell drug response measurements via live cell interferometry
CA2752008A1 (en) 2011-09-13 2013-03-13 Universite De Montreal Combination therapy using ribavirin as elf4e inhibitor
EP3004373B1 (en) 2013-05-24 2018-03-14 The Regents of The University of California Identifying desirable t lymphocytes by change in mass responses
WO2020214806A1 (en) * 2019-04-16 2020-10-22 The Regents Of The University Of California Protein translational control

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1010380A (en) * 1963-08-07 1965-11-17 Shionogi & Co Antibiotic showdomycin and a process for its production
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
FI63596C (fi) 1981-10-16 1983-07-11 Orion Yhtymae Oy Mikrobdiagnostiskt foerfarande som grundar sig pao skiktshybridisering av nukleinsyror och vid foerfarandet anvaenda kombinationer av reagenser
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
FI71768C (fi) 1984-02-17 1987-02-09 Orion Yhtymae Oy Foerbaettrade nykleinsyrareagenser och foerfarande foer deras framstaellning.
GB8432118D0 (en) 1984-12-19 1985-01-30 Malcolm A D B Sandwich hybridisation technique
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4751177A (en) 1985-06-13 1988-06-14 Amgen Methods and kits for performing nucleic acid hybridization assays
GB8800276D0 (en) * 1988-01-07 1988-02-10 Univ Liverpool Medical treatment
WO1990001564A1 (en) 1988-08-09 1990-02-22 Microprobe Corporation Methods for multiple target analyses through nucleic acid hybridization
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
JPH0874B2 (ja) 1990-07-27 1996-01-10 アイシス・ファーマシューティカルス・インコーポレーテッド 遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304620D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Compounds
WO1995013377A1 (en) 1993-11-12 1995-05-18 Case Western Reserve University Episomal expression vector for human gene therapy
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
GB9525639D0 (en) 1995-12-15 1996-02-14 Isis Innovation Improved retroviral vectors
US6129705A (en) 1997-10-01 2000-10-10 Medtronic Ave, Inc. Drug delivery and gene therapy delivery system
US6230802B1 (en) 1998-07-24 2001-05-15 Schlumberger Technology Corporation Method and apparatus for gravel packing a well
US6135976A (en) 1998-09-25 2000-10-24 Ekos Corporation Method, device and kit for performing gene therapy
US7638496B2 (en) * 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US6673775B2 (en) * 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
JP2005524662A (ja) * 2002-02-28 2005-08-18 ビオタ インコーポレーティッド ヌクレオシド５’−一リン酸模倣物およびこれらのプロドラッグ
WO2004012769A1 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California Therapeutic inhibitionof protein kinases in cancer cells
CA2566874C (en) * 2003-05-15 2014-07-08 Hemosol Lp Targeted delivery of anti-viral compounds through hemoglobin bioconjugation
AU2004256425A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Also Published As

Publication number Publication date
EP1971690B1 (en) 2018-10-17
CA2633715A1 (en) 2007-11-01
EP1971690A4 (en) 2009-11-11
JP2016040263A (ja) 2016-03-24
AU2006342447A1 (en) 2007-11-01
WO2007123579A3 (en) 2008-02-28
AU2006342447B2 (en) 2013-06-20
CA2633715C (en) 2016-06-14
WO2007123579A2 (en) 2007-11-01
WO2007123579B1 (en) 2008-04-24
JP2009522281A (ja) 2009-06-11
EP1971690A2 (en) 2008-09-24

Similar Documents

Publication Publication Date Title
JP7323592B2 (ja) 癌を治療するための併用療法
US10472677B2 (en) Translational dysfunction based therapeutics
Fiskus et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells
Astudillo et al. The small molecule IMR-1 inhibits the notch transcriptional activation complex to suppress tumorigenesis
Schiewer et al. Dual roles of PARP-1 promote cancer growth and progression
Mondello et al. Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma
Mackintosh et al. WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells
ES2527361T3 (es) Métodos y composiciones para el tratamiento del cáncer
JP2016040263A (ja) 翻訳機能障害に基づく治療法
Saito et al. Eradication of central nervous system leukemia of T-cell origin with a brain-permeable LSD1 inhibitor
EP3327144B1 (en) Novel androgen receptor mutation
WO2020023768A1 (en) Methods and materials for identifying and treating bet inhibitor-resistant cancers
Ricci et al. Novel ABCG2 antagonists reverse topotecan-mediated chemotherapeutic resistance in ovarian carcinoma xenografts
Galbán et al. A bifunctional MAPK/PI3K antagonist for inhibition of tumor growth and metastasis
Zang et al. Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s
Göbel et al. Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of diffuse large B-cell lymphoma
US20240050392A1 (en) Compositions and methods for improved treatment of platinum-based chemotherapeutic resistant tumors
JP7684910B2 (ja) 小児対象において神経膠腫を治療するためのｔｇ０２の使用
Class et al. Patent application title: TRANSLATIONAL DYSFUNCTION BASED THERAPEUTICS Inventors: Gordon A. Jamieson, Jr.(Arlington, MA, US) Katherine LB Borden (St. Laurent, CA) Biljana Culjkovic (Montreal, CA) Alex Kentsis (New York, NY, US) Assignees: Translational Therapeutics, Inc.
US20220307030A1 (en) Uses of synthetic lethal partners for treatment of cancer
US20240398814A1 (en) Kras inhibitor and hdac inhibitor combination for the treatment of cancer
US20220193056A1 (en) Compositions and methods of treating pik3ca helical domain mutant cancers
WO2023141648A1 (en) 2-fluoroethyl procarbazine compounds
CN119997943A (zh) 用于治疗具有改变的stk11活性或表达的癌症的hdac抑制剂
Bernasconi Epigenome as a therapeutic target for lymphoma

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 DEC 2016 BY CPA GLOBAL

Effective date: 20131227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2017 BY CPA GLOBAL

Effective date: 20161223

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2018 BY CPA GLOBAL

Effective date: 20171227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2019 BY CPA GLOBAL

Effective date: 20181227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2020 BY CPA GLOBAL

Effective date: 20191231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2021 BY CPA GLOBAL

Effective date: 20201231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2022 BY CPA GLOBAL

Effective date: 20220121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2023 BY CPA GLOBAL

Effective date: 20230210

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2024 BY CPA GLOBAL

Effective date: 20240628

LAPS Patent lapsed